PT-141
Also known as: Bremelanotide, Vyleesi
A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder. Works on the central nervous system rather than the vascular system.
Mechanism of Action
Activates MC3R and MC4R melanocortin receptors in the hypothalamus, stimulating sexual arousal pathways in the CNS.
Dosing Protocol
500-1500 mcg subcutaneous, 45 minutes before activity. Max once per 24 hours, max 8 doses/month.
Open peptide calculatorReconstitution
10mg vial + 2mL BAC water = 5000 mcg/mL.
Storage
Lyophilized: -20°C. Reconstituted: 2-8°C.
Side Effects
- ●Nausea (common)
- ●Flushing
- ●Headache
- ●Skin darkening with repeated use
Key Research Findings
- ●FDA-approved as Vyleesi for HSDD in premenopausal women
- ●Effective in both male and female arousal in clinical trials
- ●CNS-mediated mechanism unlike PDE5 inhibitors
Latest Verified Lab Report
No lab reports available for PT-141 yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Active Deals
15% off with code at checkout.
10% off with code at checkout.
10% off — discount applied automatically via referral link.
10% off with code at checkout.
Sponsored Ad Space
Advertise with usResearch Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.